Premium
Clinical trial of Δ 1 ‐testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer: A report of the cooperative breast cancer group
Author(s) -
Goldenberg Ira S.
Publication year - 1969
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1
Subject(s) - medicine , cancer , breast cancer , medroxyprogesterone acetate , oncology , gynecology , estrogen
Three hundred and nineteen women with advanced and metastatic carcinoma of the breast were treated according to the protocol of the Cooperative Breast Cancer Group with one of three compounds: Δ 1 ‐testololactone, micronized medroxy progesterone acetate or oxylone acetate. Drugs were supplied by the Cancer Chemotherapy National Service Center. NSC 23759: 17 alpha‐oxa‐D‐homandrosta‐1, 4‐diene‐3, 17 dione; NSC 26386: Pregna‐4‐ene‐3, 20‐dione, 17‐hydroxy‐6, alpha‐methyl‐, acetate; NSC 47438: 9 alpha‐pregna‐1, 4‐diene‐3, 20‐dione, 9‐fluoro‐11 beta, 17‐dihydroxy‐6 alpha‐methyl‐, 17 acetate. The oxylone produced 19.4% objective remissions, the progesterone 9.3% and the Δ 1 ‐testololactone, 4.9%. Women who responded to therapy with any of these drugs had a better survival experience than those who did not since 50% of the responders were dead 21 months from the start of therapy but 50% of the non‐responders were dead 6 months thereafter. Although oxylone caused a moderate degree of difficulty with steroid effects, it might be considered effective therapy for advanced mammary cancer, especially as secondary therapy.